目的　评价FAP经肝动脉灌注联合全身化疗对肝转移癌的治疗效果。　方法　经CT或MRI诊断 2 3例肝多发转移癌患者 ,采用表阿霉素 (EPI) 4 0mg/m2 ,顺铂 (CDDP) 6 0mg/m2 ,经肝动脉灌注(d1)。 5 -氟尿嘧啶 (5 -FU) 5 0 0mg/m2 经静脉给药 (d1,d8)。所有患者治疗 2～ 4个周期后复查CT或MRI。　结果　本组有效率为 74 %。 1年、2年和 3年生存率分别为 88 8%± 7 9% ;6 6 9%± 12 3%和2 4 6 %± 2 3 4 %。中位生存期为 2 5个月。　结论　FAP方案是一种传统的化疗方案 ,改变给药途径可提高肝转移癌的疗效 ,延长生存期 Objective To evaluate the therapeutic effect of FAP on hepatic metastases by hepatic artery perfusion combined with systemic chemotherapy. Methods Twenty-three patients with multiple liver metastasis were diagnosed by CT or MRI. The patients were treated with epirubicin (EPI) 40 mg / m2 and cisplatin (CDDP) 60 mg / m2 and hepatic artery perfusion (d1). 5 - fluorouracil (5 -FU) 500 mg / m2 intravenously (d1, d8). All patients were reviewed after 2 to 4 cycles of CT or MRI. Results The effective rate of this group was 74%. The 1-year, 2-year and 3-year survival rates were 88 8% ± 7 9%, 6 6 9% ± 12 3% and 24 6% ± 2 3 4%, respectively. Median survival was 25 months. Conclusion The FAP regimen is a traditional chemotherapy regimen. Changing the route of administration can improve the curative effect of liver metastatic carcinoma and prolong the survival period